Beetham Thomas W.
Beetham Thomas W.'s purchase track record
Beetham Thomas W. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/27/2024 | VRDN | $117K | -16.6% | -38.1% | -2.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants. Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.
Transaction History
| VRDN | ▲ Buy | Option Exercise | 9,409 | — | 3/3/2026 | View on chart |
| VRDN | ▼ Sell | Tax Withholding | 3,138 | $92K | 3/3/2026 | View on chart |
| VRDN | ▲ Buy | Open Market | 5,000 | $117K | 9/27/2024 | View on chart |
| DNTH | ▲ Buy | Grant | 3,000 | $3K | 11/30/2022 | View on chart |
| DNTH | ▲ Buy | Grant | 3,000 | $3K | 5/31/2022 | View on chart |
| DNTH | ▼ Sell | Open Market | 6,103 | $41K | 9/16/2021 | View on chart |
| DNTH | ▲ Buy | Grant | 20,000 | $0 | 9/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
VRDN Draws Institutional Interest; Set for Wells Fargo Healthcare Conference
Viridian Therapeutics has attracted attention as a healthcare specialist identified it among four biotech stocks of interest, according to Benzinga. The company is scheduled to present at the Wells Fargo Healthcare Conference, a routine industry event for biotech firms seeking investor engagement. The stock is currently trading within its 52-week range of $13.18 to $34.29, while analysts maintain an average price target of $36.62 based on 16 estimates.
VRDN Draws Institutional Interest; Set for Wells Fargo Healthcare Conference. Viridian Therapeutics has attracted attention as a healthcare specialist identified it among four biotech stocks of interest, according to Benzinga. The company is scheduled to present at the Wells Fargo Healthcare Conference, a routine industry event for biotech firms seeking investor engagement. The stock is currently trading within its 52-week range of $13.18 to $34.29, while analysts maintain an average price target of $36.62 based on 16 estimates.